VINBLASTINE

Search structure
Synonyms:
Status: Approved (1965)
Entry Type: Small molecule
Molecule Category: Parent
ATC: L01CA01
UNII: 5V9KLZ54CY

Structure
InChI Key JXLYSJRDGCGARV-CFWMRBGOSA-N
Smile CC[C@]1(O)C[C@@H]2CN(CCc3c([nH]c4ccccc34)[C@@](C(=O)OC)(c3cc4c(cc3OC)N(C)[C@H]3[C@@](O)(C(=O)OC)[C@H](OC(C)=O)[C@]5(CC)C=CCN6CC[C@]43[C@@H]65)C2)C1
InChI
InChI=1S/C46H58N4O9/c1-8-42(54)23-28-24-45(40(52)57-6,36-30(15-19-49(25-28)26-42)29-13-10-11-14-33(29)47-36)32-21-31-34(22-35(32)56-5)48(4)38-44(31)17-20-50-18-12-16-43(9-2,37(44)50)39(59-27(3)51)46(38,55)41(53)58-7/h10-14,16,21-22,28,37-39,47,54-55H,8-9,15,17-20,23-26H2,1-7H3/t28-,37-,38+,39+,42-,43+,44+,45-,46-/m0/s1

Physicochemical Descriptors

Property Name Value
Molecular Formula C46H58N4O9
Molecular Weight 810.99
AlogP 3.99
Hydrogen Bond Acceptor 12.0
Hydrogen Bond Donor 3.0
Number of Rotational Bond 7.0
Polar Surface Area 154.1
Molecular species BASE
Aromatic Rings 3.0
Heavy Atoms 59.0

Experimental and Estimated Properties

Property Name Value Unit Method
log P (octanol-water) 3.7 - EXP
Atmospheric OH Rate Constant 6.44E-10 cm3/molecule-sec EST

Pharmacology

Targets EC50(nM) IC50(nM) Kd(nM) Ki(nM) Inhibition(%)
Enzyme Cytochrome P450 Cytochrome P450 family 3 Cytochrome P450 family 3A Cytochrome P450 3A4
- 26000 - - -
Enzyme Oxidoreductase
- - - 77000-77000 -
Structural protein
200 600-1600 - - 50-74
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC21/SLCO family of organic anion transporting polypeptides
- 43500 - 10200 54-82
Transporter Electrochemical transporter SLC superfamily of solute carriers SLC22 family of organic cation and anion transporters
- - - - 2
Transporter Primary active transporter ATP-binding cassette ABCB subfamily
- 2000-34000 - 100-1300 75

Indications

Mesh Heading Maximum Phase Mesh ID Reference
Neoplasms 4 D009369 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Lymphoma, Large B-Cell, Diffuse 3 D016403 ClinicalTrials
Leukemia 3 D007938 ClinicalTrials
Lymphoma 3 D008223 ClinicalTrials
Skin Neoplasms 3 D012878 ClinicalTrials
Urethral Neoplasms 3 D014523 ClinicalTrials
Prostatic Neoplasms, Castration-Resistant 3 D064129 ClinicalTrials
Lung Neoplasms 3 D008175 ClinicalTrials
Hodgkin Disease 3 D006689 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Hodgkin Disease 3 D006689 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Melanoma 3 D008545 ClinicalTrials
Histiocytosis, Langerhans-Cell 3 D006646 ClinicalTrials
Lymphoma, T-Cell, Peripheral 3 D016411 ClinicalTrials
Testicular Neoplasms 3 D013736 ClinicalTrials
Urinary Bladder Neoplasms 3 D001749 ClinicalTrials
Glioma 2 D005910 ClinicalTrials
Carcinoma, Renal Cell 2 D002292 ClinicalTrials
Neurofibromatosis 1 2 D009456 ClinicalTrials
Constriction, Pathologic 2 D003251 ClinicalTrials
Precursor Cell Lymphoblastic Leukemia-Lymphoma 2 D054198 ClinicalTrials
Central Nervous System Neoplasms 1 D016543 ClinicalTrials

Related Entries

Scaffolds

Salt

Cross References

Resources Reference
CAS NUMBER 865-21-4
ChEMBL CHEMBL159
DrugBank DB00570
DrugCentral 2823
EPA CompTox DTXSID8021430
FDA SRS 5V9KLZ54CY
Guide to Pharmacology 6851
PDB VLB
PubChem 13342
SureChEMBL SCHEMBL3628
ZINC ZINC000085432544
CONTENTS